-
-
-
-
-
-
-
Cogent (COGT) PT Raised to $55 at H.C. Wainwright
-
-
-
-
-
-
-
Cogent (COGT) PT Raised to $52; Piper Sandler 'Remain Buyers Ahead of 2H26 Bezuclastinib Launch'
-
-
-
-
-
-
-
Cogent Biosciences (COGT) call put ratio 3.4 calls to 1 put as share price up 2.1%
-
-
-
-
-
-
-
Cogent's (COGT) Bezuclastinib Up For Approval in 2026 - Stifel
-
-
-
-
-
-
-
Stifel Upgrades Cogent (COGT) to Buy
-
-
-
-
-
-
-
This biotech stock is a Top Pick at Raymond James
-
-
-
-
-
-
-
Cogent Biosciences completes upsized $230 million public offering
-
445,608 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

